Avantor, Inc.

Avantor, Inc.(AVTR)の株式分析

$16.420

+0.337 (+2.05%)終値時点

Loading chart…
高値
16.450
始値
16.100
出来高加重平均価格
16.27
出来高
29.36M
時価総額
14.55B
安値
15.950
売買代金
477.73M
EV/EBITDA(TTM)
15.84

Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company's segments include Bioscience & Medtech Products and VWR Distribution & Services. Through these segments, it provides materials and consumables, equipment and instrumentation and services and specialty procurement to customers in biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and others.

AI分析 of Avantor, Inc. (AVTR)

買い

Avantor Inc is a good buy right now due to its current price of $16.42, which is below the analyst price targets of $15 to $17, suggesting upside potential. The stock has shown a strong year-to-date change of +43.28%, indicating positive momentum. However, the company has faced challenges with a negative net income in Q3 2025, which is a risk to consider.

バリュエーション指標

Avantor, Inc.(AVTR)の現在の予想PERは16.86で、5年平均は18.34です。

予想PER

適正
5年平均 P/E
18.34
現在のP/E
16.86
割高
23.27
割安
13.41

予想EV/EBITDA

適正
5年平均 EV/EBITDA
17.57
現在のEV/EBITDA
15.84
割高
31.24
割安
3.89

予想PSR

適正
5年平均 P/S
1.94
現在のP/S
1.61
割高
2.53
割安
1.35

Alphio AI による AVTR の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%AVTR

$16.34

シナリオ価格

基

基本

基本 · 50%AVTR

$14.73

シナリオ価格

弱

弱気

弱気 · 25%AVTR

$12.25

シナリオ価格

AVTR を保有するクジラ

Y

Yacktman Asset Management LP

+ を保有AVTR

+7.03%

3か月リターン

N

NewSouth Capital Management, Inc.

+ を保有AVTR

-3.24%

3か月リターン

V

Voss Capital, LP

+ を保有AVTR

-5.54%

3か月リターン

P

Prescott General Partners LLC

+ を保有AVTR

-9.05%

3か月リターン

L

Loews Corporation

+ を保有AVTR

-9.47%

3か月リターン

イベントタイムライン

2026-09-21 (ET)

06:30:00

Avantor Appoints Todd Garner as EVP and CFO

2026-07-29 (ET)

17:00:00

Federal Reserve Holds Rates Steady, Major Indices Drop Significantly

12:30:00

Dow Jones Drops 874.35 Points as Oil Prices Surge

06:30:00

Company Reports Q2 Revenue of $1.69B, Exceeding Expectations

06:30:00

Raises FY26 Organic Revenue View to Down 0.5% to Up 0.5%

ニュース

AVTR のよくある質問 — Alphio AI が回答

Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company's segments include Bioscience & Medtech Products and VWR Distribution & Services. Through these segments, it provides materials and consumables, equipment and instrumentation and services and specialty procurement to customers in biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Avantor Inc is a good buy right now due to its current price of $16.42, which is below the analyst price targets of $15 to $17, suggesting upside potential. The stock has shown a strong year-to-date change of +43.28%, indicating positive momentum. However, the company has faced challenges with a negative net income in Q3 2025, which is a risk to consider.

コミュニティ

もっと見る ↗
登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める